Pulmonx Co. (NASDAQ:LUNG) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Pulmonx Co. (NASDAQ:LUNG) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $15.71.

Several analysts have commented on LUNG shares. Piper Sandler reiterated an “overweight” rating and issued a $17.00 price target on shares of Pulmonx in a research note on Wednesday, April 3rd. Canaccord Genuity Group dropped their price target on Pulmonx from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, May 2nd. Finally, Lake Street Capital began coverage on Pulmonx in a report on Tuesday, June 4th. They set a “buy” rating and a $12.00 price target for the company.

Pulmonx Stock Performance

Shares of NASDAQ LUNG opened at $6.34 on Wednesday. The stock has a market cap of $246.12 million, a PE ratio of -4.12 and a beta of 0.64. Pulmonx has a 1 year low of $5.67 and a 1 year high of $14.84. The firm has a fifty day moving average price of $7.55 and a 200-day moving average price of $9.96. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.95 and a quick ratio of 6.14.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, May 1st. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative return on equity of 48.09% and a negative net margin of 80.46%. The company had revenue of $18.85 million for the quarter, compared to the consensus estimate of $17.54 million. During the same quarter last year, the company earned ($0.42) EPS. Equities analysts anticipate that Pulmonx will post -1.63 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Geoffrey Beran Rose sold 4,297 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $6.97, for a total value of $29,950.09. Following the completion of the sale, the insider now directly owns 301,203 shares in the company, valued at $2,099,384.91. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, General Counsel David Aaron Lehman sold 5,475 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $6.97, for a total value of $38,160.75. Following the sale, the general counsel now directly owns 209,113 shares of the company’s stock, valued at approximately $1,457,517.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Geoffrey Beran Rose sold 4,297 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $6.97, for a total value of $29,950.09. Following the transaction, the insider now owns 301,203 shares of the company’s stock, valued at approximately $2,099,384.91. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,324 shares of company stock valued at $94,585. 5.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pulmonx

Institutional investors and hedge funds have recently modified their holdings of the business. Quest Partners LLC purchased a new stake in Pulmonx in the fourth quarter worth $94,000. Allspring Global Investments Holdings LLC increased its position in shares of Pulmonx by 609.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after acquiring an additional 7,316 shares during the period. SG Americas Securities LLC bought a new stake in shares of Pulmonx during the fourth quarter valued at approximately $117,000. Aigen Investment Management LP purchased a new stake in shares of Pulmonx in the third quarter valued at approximately $111,000. Finally, EntryPoint Capital LLC bought a new position in Pulmonx in the first quarter worth approximately $102,000. 91.04% of the stock is owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.